THE EFFECT OF A LOW-DOSE OF QUINIDINE ON THE DISPOSITION OF FLECAINIDE IN HEALTHY-VOLUNTEERS

被引:10
作者
MUNAFO, A
BUCLIN, T
TUTO, D
BIOLLAZ, J
机构
[1] Centre Hospitalier Universitaire Vaudois, Division de Pharmacologie Clinique, Lausanne, CH-1011
关键词
FLECAINIDE; QUINIDINE; PHARMACOKINETICS; METABOLISM INHIBITION; DRUG INTERACTION; RENAL TRANSPORT;
D O I
10.1007/BF02220625
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
We have studied the effects of quinidine on ECG intervals and on the pharmacokinetics of flecainide and its two metabolites in 6 healthy men in an open randomized crossover study. Flecainide acetate (150 mg) was given as a constant rate i.v. infusion over 30 min. Quinidine (50 mg orally), given the previous evening, did not change the volume of distribution of flecainide (7.9 vs 7.4 l . kg-1), but significantly increased its half-life (8.8 vs 10.7 h). This was attributable to a reduction in total clearance (10.6 vs 8.1 ml . min-1 . kg-1), most of it being accounted for by a reduction in non-renal clearance (7.2 vs 5.2 ml . min-1 . kg-1). The excretion of the metabolites of flecainide over 48 h was significantly reduced. These findings suggest that quinidine inhibits the first step of flecainide metabolism, although it may also reduce its renal clearance, but to a lesser extent (3.5 vs 2.9 ml . min-1 . kg-1). The effects of flecainide on ECG intervals were not altered by quinidine. Thus, quinidine tends to shift extensive metabolizer status for flecainide towards poor metabolizer status and may also alter its renal excretion.
引用
收藏
页码:441 / 443
页数:3
相关论文
共 24 条
[1]  
[Anonymous], 1989, NEW ENGL J MED, V321, P406
[2]  
ARONSON JK, 1981, LANCET, V1, P1418
[3]   SPARTEINE OXIDATION IS PRACTICALLY ABOLISHED IN QUINIDINE-TREATED PATIENTS [J].
BRINN, R ;
BROSEN, K ;
GRAM, LF ;
HAGHFELT, T ;
OTTON, SV .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1986, 22 (02) :194-197
[4]   QUINIDINE INHIBITS THE 2-HYDROXYLATION OF IMIPRAMINE AND DESIPRAMINE BUT NOT THE DEMETHYLATION OF IMIPRAMINE [J].
BROSEN, K ;
GRAM, LF .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1989, 37 (02) :155-160
[5]   RECENT DEVELOPMENTS IN HEPATIC DRUG OXIDATION - IMPLICATIONS FOR CLINICAL PHARMACOKINETICS [J].
BROSEN, K .
CLINICAL PHARMACOKINETICS, 1990, 18 (03) :220-239
[6]   METABOLISM OF FLECAINIDE [J].
CONARD, GJ ;
OBER, RE .
AMERICAN JOURNAL OF CARDIOLOGY, 1984, 53 (05) :B41-B51
[7]   IMPACT OF ENVIRONMENTAL AND GENETIC-FACTORS ON CODEINE ANALGESIA [J].
DESMEULES, J ;
GASCON, MP ;
DAYER, P ;
MAGISTRIS, M .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1991, 41 (01) :23-26
[8]  
EICHELBAUM M, 1988, PHARMACOLOGY, V3, P243
[9]  
FUNCKBRENTANO C, 1989, J PHARMACOL EXP THER, V249, P134
[10]   STEREOSELECTIVE DISPOSITION OF FLECAINIDE IN RELATION TO THE SPARTEINE DEBRISOQUINE METABOLIZER PHENOTYPE [J].
GROSS, AS ;
MIKUS, G ;
FISCHER, C ;
HERTRAMPF, R ;
GUNDERTREMY, U ;
EICHELBAUM, M .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1989, 28 (05) :555-566